Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • RegenxBio, Dimension Therapeutics deal

    RegenxBio Inc., Washington, D.C. Dimension Therapeutics Inc., Cambridge, Mass. Business: Endocrine/Metabolic The partners disclosed that Dimension selected the remaining two indications covered under a 2013 deal …

    Published on 5/25/2015
  • Regimmune, Pfizer, JDRF deal

    Regimmune Corp., Tokyo, Japan Pfizer Inc. (NYSE:PFE), New York, N.Y. JDRF, New York, N.Y. Business: Endocrine/Metabolic Regimmune, JDRF and Pfizer partnered to develop an antigen-specific immunotherapy using Regimmunes …

    Published on 5/25/2015
  • Roche, Astellas deal

    Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Pharmacogenetics Roches Ventana Medical Systems Inc. unit will develop companion diagnostics for compounds being …

    Published on 5/25/2015
  • Samyang, Sorrento deal

    Samyang Corp. (KSE:000070), Seoul, South Korea Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Business: Cancer Samyang granted Sorrentos Igdrasol Inc. subsidiary exclusive rights to commercialize cancer …

    Published on 5/25/2015
  • Sanofi, Cystic Fibrosis Foundation deal

    Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Cystic Fibrosis Foundation, Bethesda, Md. Business: Pulmonary Sanofis Genzyme Corp. unit and the foundations drug development arm expanded a November 2011 to discover …

    Published on 5/25/2015
  • Sun Pharmaceutical, Technion - Israel Institute of Technology deal

    Sun Pharmaceutical Industries Ltd. (BSE:524715;NSE:SUNPHARMA), Mumbai, India Technion - Israel Institute of Technology, Haifa, Israel Business: Cancer Subsidiaries of Sun and Technion partnered to jointly develop cancer…

    Published on 5/25/2015
  • Taxus Cardium, Shenzhen Qianhai Taxus Industry Capital Management Co. Ltd. deal

    Taxus Cardium Pharmaceuticals Group Inc. (OTCQB:CRXM), San Diego, Calif. Shenzhen Qianhai Taxus Industry Capital Management Co. Ltd., Shenzhen, China Business: Dermatology, Cardiovascular Taxus Cardium granted Shenzhen …

    Published on 5/25/2015
  • ThromboGenics, Flanders Institute for Biotechnology (VIB), Oncurious deal

    ThromboGenics N.V. (Euronext:THR), Leuven, Belgium Flanders Institute for Biotechnology (VIB), Ghent, Belgium Oncurious N.V., Leuven, Belgium Business: Cancer ThromboGenics and VIB launched Oncurious, a new company with…

    Published on 5/25/2015
  • TPG Capital, Endo deal

    TPG Capital, Fort Worth, Texas Endo International plc (NASDAQ:ENDP;TSX:ENL), Dublin, Ireland Business: Generics Endo will acquire generics company Par Pharmaceutical Cos. Inc. (Woodcliff Lake, N.J.) from investment firm…

    Published on 5/25/2015
  • Trojantec, Sellas deal

    Trojantec Ltd., Nicosia, Cyprus Sellas Life Sciences Group, Zurich, Switzerland Business: Cancer Trojantec granted Sellas exclusive, worldwide rights to develop and commercialize TR-1 cancer therapeutic technology and …

    Published on 5/25/2015
  • Veracyte, General Electric deal

    Veracyte Inc. (NASDAQ:VCYT), South San Francisco, Calif. General Electric Co. (NYSE:GE), Fairfield, Conn. Business: Diagnostic Veracyte partnered with the Ventures, Healthcare and Global Research Center units of GE to …

    Published on 5/25/2015
  • WaferGen, Genentech, Roche deal

    WaferGen Bio-systems Inc. (NASDAQ:WGBS), Fremont, Calif. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Genomics WaferGen non-exclusively partnered with Roches …

    Published on 5/25/2015
  • Actavis, TPG Capital deal

    Actavis Group, Zug, Switzerland TPG Capital, Fort Worth, Texas Business: Supply/Service Actavis completed the divestiture of its Aptalis Pharmaceutical Technologies subsidiary to private investment firm TPG for an …

    Published on 5/18/2015
  • AM-Pharma, Pfizer deal

    AM-Pharma B.V., Bunnik, the Netherlands Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Renal Pfizer purchased a 17.5% equity stake in AM-Pharma and received an option acquire the remainder of the company. The option …

    Published on 5/18/2015
  • AOP Orphan, Cardiome deal

    AOP Orphan Pharmaceuticals AG, Vienna, Austria Cardiome Pharma Corp. (TSX:COM;NASDAQ:CRME), Vancouver, B.C. Business: Cardiovascular AOP Orphan granted Cardiome rights to market IV and powder formulations of Esmocard …

    Published on 5/18/2015
  • Arena, Roivant Sciences deal

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Roivant Sciences Ltd., New York, N.Y. Business: Neurology Arena granted Roivant exclusive, worldwide rights to develop and commercialize nelotanserin. Arena …

    Published on 5/18/2015
  • BioNTech, Eli Lilly deal

    BioNTech AG, Mainz, Germany Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Cancer The partners will identify and validate tumor targets and their corresponding T cell receptors (TCR) in one or more …

    Published on 5/18/2015
  • Biosearch Technologies, LGC deal

    Biosearch Technologies Inc., Novato, Calif. LGC Ltd., Teddington, U.K. Business: Supply/Service Analytical testing company LGC acquired custom oligonucleotide manufacturer Biosearch for an undisclosed cash sum. …

    Published on 5/18/2015
  • ChemRar, Lancet deal

    ChemRar High Tech Center, Khimki, Russia Lancet JSC, Moscow, Russia Business: Pharmaceuticals ChemRar and Lancet partnered to develop and commercialize drug candidates in the Eurasian Economic Union, which includes …

    Published on 5/18/2015
  • Coherus BioSciences, Baxter deal

    Coherus BioSciences Inc. (NASDAQ:CHRS), Redwood City, Calif. Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Business: Autoimmune, Biosimilars Coherus will perform preclinical development and will be eligible for …

    Published on 5/18/2015
  • Eli Lilly, Transition Therapeutics deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Transition Therapeutics Inc. (TSX:TTH;NASDAQ:TTHI), Toronto, Ontario Business: Endocrine/Metabolic Eli Lilly granted Transitions Transition Therapeutics Ireland Ltd. …

    Published on 5/18/2015
  • Evolva Holding, Emergent BioSolutions deal

    Evolva Holding S.A. (SIX:EVE), Reinach, Switzerland Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. Business: Infectious Emergent acquired Evolvas EV-035 antibiotic portfolio, including preclinical melioidosis …

    Published on 5/18/2015
  • FibroGen, AstraZeneca deal

    FibroGen Inc. (NASDAQ:FGEN), San Francisco, Calif. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Hematology FibroGen received a $15 million milestone payment from AstraZeneca under a 2013 deal to develop …

    Published on 5/18/2015
  • Fondazione Tettamanti, Formula Pharmaceuticals deal

    Fondazione Matilde Tettamanti Menotti De Marchi Onlus, Monza, Italy Formula Pharmaceuticals Inc., Berwyn, Pa. Business: Cancer Fondazione Tettamanti granted Formula exclusive, worldwide rights to develop and …

    Published on 5/18/2015
  • GeoVax Labs, NIH deal

    GeoVax Labs Inc. (OTCBB:GOVX), Atlanta, Ga. National Institutes of Health, Bethesda, Md. Business: Infectious GeoVax and NIHs National Institute of Allergy and Infectious Diseases (NIAID) partnered to develop GeoVaxs …

    Published on 5/18/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993